Novavax, Inc [NASDAQ: NVAX] loss -4.08% or -0.32 points to close at $7.52 with a heavy trading volume of 8062702 shares.
It opened the trading session at $7.85, the shares rose to $7.85 and dropped to $7.44, the range by which the price of stock traded the whole day. The daily chart for NVAX points out that the company has recorded 1.48% gains over the past six months.
If we look at the average trading volume of 6.53M shares, NVAX reached to a volume of 8062702 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Novavax, Inc [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $12.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Novavax, Inc shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 20, 2025. While these analysts kept the previous recommendation, Citigroup raised their target price to Sell. The new note on the price target was released on June 17, 2025, representing the official price target for Novavax, Inc stock. Previously, the target price had yet another raise to $19, while BTIG Research analysts kept a Buy rating on NVAX stock.
The Price to Book ratio for the last quarter was 32.41, with the Price to Cash per share for the same quarter was set at 3.84.
Trading performance analysis for NVAX stock
Novavax, Inc [NVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.55. With this latest performance, NVAX shares gained by 0.67% in over the last four-week period, additionally plugging by 1.48% over the last 6 months – not to mention a drop of -6.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 45.28, with the RSI for the last a single of trading hit 0.69, and the three-weeks RSI is set at 0.59 for Novavax, Inc [NVAX]. The present Moving Average for the last 50 days of trading for this stock 7.33, while it was recorded at 8.25 for the last single week of trading, and 7.68 for the last 200 days.
Novavax, Inc [NVAX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Novavax, Inc [NVAX] shares currently have an operating margin of 33.96% and a Gross Margin at 87.10%. Novavax, Inc’s Net Margin is presently recorded at 39.20%.
Novavax, Inc (NVAX) Capital Structure & Debt Analysis
Novavax, Inc (NVAX) Efficiency & Liquidity Metrics
Based on Novavax, Inc’s (NVAX) latest financial statements, the Debt-to-Equity Ratio is 6.07%, indicating its reliance on debt financing relative to shareholder equity.
Novavax, Inc (NVAX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Novavax, Inc. (NVAX) effectively leverages its workforce, generating an average of $444138.66 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.36% and a Quick Ratio of 2.34%, indicating strong ability to cover short-term liabilities.
Novavax, Inc [NVAX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Novavax, Inc posted -0.76/share EPS, while the average EPS was predicted by analysts to be reported at -0.78/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax, Inc go to 38.16%.
An analysis of Institutional ownership at Novavax, Inc [NVAX]
There are presently around $58.16%, or 63.74%% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 14.08 million shares, which is approximately 9.4861%. BLACKROCK INC., holding 11.85 million shares of the stock with an approximate value of $$149.98 million in NVAX stocks shares; and BLACKROCK INC., currently with $$122.32 million in NVAX stock with ownership which is approximately 6.5118%.
